Suppr超能文献

成人起病的特发性胆汁酸吸收不良的预后

Prognosis of adult-onset idiopathic bile acid malabsorption.

作者信息

Rössel P, Sortsøe Jensen H, Qvist P, Arveschoug A

机构信息

Dept. of Medical Gastroenterology, Aalborg Hospital, Denmark.

出版信息

Scand J Gastroenterol. 1999 Jun;34(6):587-90. doi: 10.1080/003655299750026047.

Abstract

BACKGROUND

From 1986 to 1993, 150 patients were investigated with the 75Se-homocholic acid taurine (SeHCAT) test as a late step in the investigation of chronic diarrhoea. On basis of low SeHCAT values and response to cholestyramine treatment, 33 patients were initially classified as having idiopathic bile acid malabsorption (IBAM). The aim was to describe the long-term clinical course of the disease and to assess the reliability of the SeHCAT test in diagnosing IBAM.

METHODS

The methods included 1) clinical follow-up with patient interview combined with information from medical records and 2) repeated SeHCAT test.

RESULTS

The diagnosis of IBAM had to be revised in three cases (inflammatory bowel disease in two patients, Clostridium difficile infection in one). Six patients were lost to follow-up and a further four patients were excluded from re-examination either because of old age (>80 years) or bowel resection, leaving 20 patients for re-examination, of which 16 completed both clinical follow-up and a new SeHCAT test. The median duration of symptoms before initial SeHCAT test was 2.5 (1-30) years. In 13 of 16 patients symptoms persisted, and SeHCAT values remained low and almost identical to the initial value after a median observation time of 88 (51-113) months. Despite initial response to treatment with cholestyramine, six patients had to discontinue treatment because of adverse effects or other compliance problems. In three patients the SeHCAT value showed a considerable increase, and bowel function had correspondingly normalized in these cases.

CONCLUSION

The study confirms the reliability of the SeHCAT test in diagnosing IBAM. Despite adult onset of symptoms, only a few patients improve after several years' observation. Treatment with cholestyramine is generally effective but not always tolerated.

摘要

背景

1986年至1993年期间,对150例慢性腹泻患者进行了75硒-高牛磺酸胆酸(SeHCAT)试验,作为慢性腹泻调查的最后一步。基于低SeHCAT值及对考来烯胺治疗的反应,33例患者最初被归类为特发性胆汁酸吸收不良(IBAM)。目的是描述该疾病的长期临床病程,并评估SeHCAT试验在诊断IBAM中的可靠性。

方法

方法包括1)通过患者访谈结合病历信息进行临床随访,以及2)重复SeHCAT试验。

结果

3例患者的IBAM诊断需修正(2例为炎症性肠病,1例为艰难梭菌感染)。6例患者失访,另有4例患者因年龄较大(>80岁)或肠道切除而被排除在重新检查之外,剩余20例患者接受重新检查,其中16例完成了临床随访和新的SeHCAT试验。首次SeHCAT试验前症状的中位持续时间为2.5(1 - 30)年。16例患者中有13例症状持续存在,中位观察时间88(51 - 113)个月后,SeHCAT值仍较低且几乎与初始值相同。尽管最初对考来烯胺治疗有反应,但6例患者因不良反应或其他依从性问题不得不停止治疗。3例患者的SeHCAT值显著升高,这些病例的肠道功能相应恢复正常。

结论

该研究证实了SeHCAT试验在诊断IBAM中的可靠性。尽管症状在成人期出现,但经过数年观察,只有少数患者病情改善。考来烯胺治疗通常有效,但并非总能耐受。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验